Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
AAC, abeyance, ablation, abscopal, Adelaide, advantage, Agex, agonist, Allan, Alvarez, amino, amphipathic, amplified, anomeric, aptamer, arm, arose, ASCO, atezolizumab, attack, augment, awarded, backbone, battle, Bensonhurst, Biju, bioavailability, Biodegradable, biomedical, bladder, block, BMS, bound, breast, Brian, burden, carbon, carcinoma, Carl, cascade, categorized, Center, ceramide, cGAMP, CGMA, characterization, characterize, characterized, chemo, chemotherapy, chose, cisplatin, clonal, cluster, Coll, configuration, consortium, cope, counter, coupled, customary, cytokine, damage, database, DC, DCs, death, Dec, dendritic, desire, destroy, diagnosed, die, differentiation, diminution, disclaimer, dislocation, disperse, displaying, diversity, docetaxel, dramatically, durable, dynamic, East, economy, Edith, educational, endocrine, Engineering, esophageal, EU, evolve, exceeded, excision, extinguishment, factor, feature, feed, Feldman, fifteenth, Floor, fluid, founder, Fujii, galactose, galactosylceramide, GalCer, gastric, glycolipid, governmental, grow, guide, hamper, harbor, hard, headcount, hemisphere, Hepatocellular, highlighted, Histocompatibility, hit, HLA, host, House, hydrophilic, IFN, IM, immunomodulatory, impinge, implicated, incidence, induction, ineffective, infarction, inflammation, inhibitor, inseen, Instance, instruct, interaction, interferon, interim, intravenously, invariant, invasive, JCH, Johnson, Juvanescence, KEYNOTE, KEYTRUDA, killer, Label, landscape, lean, legacy, length, Leukocyte, Levitsky, ligand, Linkbase, linked, lipid, liposome, literacy, llp, lung, lymphocyte, lymphokine, Marcum, Marsal, MDSC, melanoma, metastatic, methodology, MHC, MHRA, Miller, moiety, monetized, monoclonal, Morgan, murine, mutational, myocardial, Natori, Navasota, Neckonal, Nelson, neuro, NewLead, NIH, nivolumab, NK, NKT, Noncash, NSCLC, Oncomer, opportunity, optimal, organizational, oridinary, OS, Oswego, outsource, pandemic, Parekkadan, partial, partially, passage, payload, pembrolizumab, PhD, picking, play, PLGA, polar, poor, population, predefined, preservation, preset, privileged, problem, procedure, progression, prolonged, prompted, proportion, prosperity, prostate, proven, pursing, Radboud, radiation, Radiol, ratio, reality, recession, recognizable, reduction, regrowth, repaid, repertoire, reprogram, residue, resistance, resistant, risen, rolling, rooted, route, royalty, run, saddened, salarx, Salio, SalveRx, Sarcoma, satisfaction, SavaRx, SBIR, Schema, Schmieg, Schwartz, SEDAR, sensor, Serono, Shaw, shelve, shift, signaling, SLF, soft, southern, Speak, split, sponge, spread, stable, stopped, strength, strict, subset, SunnyBrook, suppressive, surgery, surgical, surpassed, survival, Syndax, synergy, synthesized, synthetic, TAM, Taxonomy, TCR, temporarily, threitol, toxic, toxicity, track, tragically, travel, Treasurer, triple, turn, undisclosed, undiscounted, undoubtedly, unemployment, Unrecognized, unsatisfactory, Uptake, USPTO, valuable, vascular, vendor, Viatel, Viking, vinblastine, Vincenzo, visible, vitro, vivo, Yervoy, young
Removed:
accepted, accredited, add, ALS, amalgamated, antagonist, Asia, Asian, Avenue, Burnbrae, CGRP, chain, Charlemagne, consuming, content, coupon, Cracking, CSO, dose, Dragon, enjoyed, episodic, ethical, excluding, explanatory, FastForward, Fax, feet, flexibility, Germany, glutamate, GT, Hare, hire, honorary, hotel, Jim, joining, landlord, launching, lawyer, lease, leased, mechanistic, migraine, modulation, narrow, necessarily, network, neurological, offset, Oriel, Pacific, Page, patented, penny, PPE, promptly, rare, Red, Regent, Rett, rimegepant, segregation, Sleepwell, square, stringent, structurally, syndrome, Tel, Thornton, trigriluzole, Uramin, volume
Filing tables
Filing exhibits
PRTG similar filings
Filing view
External links
Exhibit 15.1
CONSENT OF INDEPENDENT PUBLIC ACCOUNTING FIRM
We hereby consent to the use of our Auditors’ Report dated July 26, 2018 with respect to the consolidated financial statements of Portage Biotech Inc. (the “Company”) as at March 31, 2018 and March 31, 2017 and for the years ended March 31, 2018, 2017 and 2016 included in the Annual Report on Form 20-F of the Company for the year ended March 31, 2020.
Toronto, Ontario, Canada | Chartered Professional Accountants | ||
August 17, 2020 | Licensed Public Accountants |